$-0.51 EPS Expected for Intra-Cellular Therapies, Inc. (ITCI)

February 19, 2018 - By Henry Gaston

 $ 0.51 EPS Expected for Intra Cellular Therapies, Inc. (ITCI)
Investors sentiment increased to 2.77 in Q3 2017. Its up 1.91, from 0.86 in 2017Q2. It is positive, as 9 investors sold Intra-Cellular Therapies, Inc. shares while 21 reduced holdings. 45 funds opened positions while 38 raised stakes. 39.74 million shares or 30.25% more from 30.51 million shares in 2017Q2 were reported.
Samlyn Capital Limited Com accumulated 749,679 shares. Trexquant Investment Lp stated it has 32,176 shares or 0.13% of all its holdings. Premier Asset Mngmt Ltd Liability Corporation reported 18,429 shares. Amer Gp has invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Moreover, Numeric Limited Com has 0.01% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Weiss Multi accumulated 104,700 shares. Hanseatic Mgmt Inc stated it has 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). State Board Of Administration Of Florida Retirement Sys owns 15,495 shares. Barclays Public Limited reported 0% stake. Omers Administration invested in 14,400 shares or 0% of the stock. 669,140 are held by Deutsche Bank Ag. Virtu Financial Ltd Co invested 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Perceptive Ltd Company owns 929,460 shares or 0.56% of their US portfolio. Price T Rowe Incorporated Md has invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Moreover, Stifel Corporation has 0% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 14,850 shares.

Since September 29, 2017, it had 3 insider buys, and 9 insider sales for $10.92 million activity. 5,062 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares with value of $82,725 were sold by Hineline Lawrence J.. ALAFI CAPITAL CO LLC bought $4.00 million worth of stock. Halstead Michael sold $69,179 worth of stock. Shares for $17,394 were sold by Davis Robert E. Mates Sharon had sold 6,604 shares worth $115,438. 258,065 shares were bought by Alafi Christopher D, worth $4.00 million on Friday, September 29.

Analysts expect Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report $-0.51 EPS on March, 7.They anticipate $0.13 EPS change or 20.31 % from last quarter’s $-0.64 EPS. After having $-0.53 EPS previously, Intra-Cellular Therapies, Inc.’s analysts see -3.77 % EPS growth. The stock decreased 0.15% or $0.03 during the last trading session, reaching $19.97. About 486,573 shares traded or 10.56% up from the average. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has declined 68.76% since February 19, 2017 and is downtrending. It has underperformed by 85.46% the S&P500.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Ratings Coverage

Among 11 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. Intra-Cellular Therapies had 36 analyst reports since August 6, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained the shares of ITCI in report on Wednesday, November 8 with “Buy” rating. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, August 23 report. The rating was maintained by JMP Securities on Wednesday, March 9 with “Market Outperform”. The company was maintained on Tuesday, June 6 by Cowen & Co. RBC Capital Markets maintained it with “Outperform” rating and $74 target in Friday, November 6 report. As per Thursday, September 29, the company rating was downgraded by SunTrust. The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has “Market Outperform” rating given on Thursday, August 24 by JMP Securities. Cantor Fitzgerald maintained Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) rating on Wednesday, August 9. Cantor Fitzgerald has “Buy” rating and $2900 target. The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has “Buy” rating given on Wednesday, August 9 by Cowen & Co. The firm has “Buy” rating given on Wednesday, August 23 by Leerink Swann.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The company has market cap of $1.09 billion. The firm is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. It currently has negative earnings. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease.

More notable recent Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) news were published by: Globenewswire.com which released: “Intra-Cellular Therapies Reports Third Quarter 2017 Financial Results and …” on November 08, 2017, also Seekingalpha.com with their article: “Intra-Cellular Therapies: Buy, Sell Or Hold?” published on July 26, 2017, Globenewswire.com published: “Intra-Cellular Therapies to Present at the 36th Annual JP Morgan Healthcare …” on January 02, 2018. More interesting news about Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) were released by: Fool.com and their article: “The case for Intra-Cellular Therapies” published on October 21, 2017 as well as Globenewswire.com‘s news article titled: “Intra-Cellular Therapies Prices $150 Million Public Offering of Common Stock” with publication date: September 28, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.